PubRank

Caterina Musolino

Author PubWeight™ 43.54‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2012 5.87
2 Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol 2012 1.81
3 Increased serum levels of neutrophil gelatinase-associated lipocalin in patients with essential thrombocythemia and polycythemia vera. Leuk Lymphoma 2010 1.46
4 The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience. Am J Hematol 2011 1.27
5 High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications. Br J Haematol 2014 1.00
6 Concentration of circulating endothelial progenitor cells (EPC) in normal pregnancy and in pregnant women with diabetes and hypertension. Am J Obstet Gynecol 2007 0.98
7 A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. Br J Haematol 2013 0.97
8 Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features. Clin Cancer Res 2013 0.92
9 Differential levels of soluble endoglin (CD105) in myeloid malignancies. J Cell Physiol 2003 0.91
10 Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. Blood 2011 0.91
11 Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia. PLoS One 2011 0.87
12 The cancer stem cell hypothesis: a guide to potential molecular targets. Cancer Invest 2014 0.86
13 Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study. Am J Hematol 2014 0.85
14 Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma. Eur J Haematol 2013 0.85
15 JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: the role of bone marrow biopsy for the diagnosis of myeloproliferative disease. Acta Haematol 2009 0.84
16 Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia. Am J Hematol 2012 0.84
17 Endothelial progenitor cells: pathogenetic role and therapeutic perspectives. J Nephrol 2009 0.84
18 Imatinib mesylate therapy induces reduction in neutrophil gelatinase-associated lipocalin serum levels and increase in leptin concentrations in chronic myeloid leukemia patients in molecular remission. Acta Haematol 2011 0.83
19 MiRNome expression is deregulated in the peripheral lymphoid compartment of multiple myeloma. Br J Haematol 2014 0.83
20 Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors. Eur J Haematol 2010 0.82
21 Oxidative stress in oncohematologic diseases: an update. Expert Rev Hematol 2013 0.82
22 Bisphosphonates induce apoptosis of circulating endothelial cells in multiple myeloma patients and in subjects with bisphosphonate-induced osteonecrosis of the jaws. Acta Haematol 2010 0.82
23 Reduced serum levels of Interleukin 17 in patients with osteonecrosis of the jaw and in multiple myeloma subjects after bisphosphonates administration. Cytokine 2008 0.81
24 Decreased plasma levels of IL-33 could contribute to the altered function of Th2 lymphocytes in patients with polycythemia vera and essential thrombocythemia. Cancer Invest 2013 0.80
25 Reduced IL-33 plasma levels in multiple myeloma patients are associated with more advanced stage of disease. Br J Haematol 2012 0.80
26 Familial B-cell chronic lymphocytic leukemia in a population of patients from Southern Italy. Int J Hematol 2004 0.79
27 Cardiac involvement in patients with hematologic malignancies. J Investig Med 2010 0.79
28 High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients. Am J Hematol 2006 0.79
29 Increase of novel biomarkers for oxidative stress in patients with plasma cell disorders and in multiple myeloma patients with bone lesions. Inflamm Res 2012 0.79
30 Involvement of T2677T multidrug resistance gene polymorphism in Interleukin 22 plasma concentration in B-chronic lymphocytic leukemia patients. Acta Oncol 2011 0.78
31 Nanoparticles in oncology: the new theragnostic molecules. Anticancer Agents Med Chem 2011 0.78
32 Patients with bisphosphonate-associated osteonecrosis of the jaw have unmodified levels of soluble vascular endothelial growth factor receptor 1. Leuk Lymphoma 2007 0.78
33 Severe dermatologic adverse reactions after exposure to lenalidomide in multiple myeloma patients with a positive HLA-DRB1*1501 and HLA-DQB1*0602. Acta Oncol 2011 0.78
34 Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study. Am J Hematol 2013 0.78
35 Immunohistochemial evaluation of sarcoglycans and integrins in gingival epithelium of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw. Oncol Rep 2010 0.77
36 Titanium miniplates: a new risk factor for the development of the bisphosphonate-related osteonecrosis of the jaw. J Craniofac Surg 2013 0.77
37 Extramedullary Plasmacytoma of the Maxilla Simulating a Maxillary Radicular Cyst: Quick Diagnosis and Management. J Craniofac Surg 2016 0.77
38 Osteosclerotic myeloma with spinal leptomeningitis and severe polyneuropathy: A case report. J Comput Assist Tomogr 2006 0.77
39 Evaluation of interleukin-23 plasma levels in patients with polycythemia vera and essential thrombocythemia. Cell Immunol 2012 0.77
40 Evaluation of interleukin-17 serum levels in patients with chronic myeloproliferative diseases. Tumori 2009 0.76
41 Avascular necrosis of bone in leukemia and osteonecrosis of jaw by bisphosphonates. J Oral Maxillofac Surg 2009 0.76
42 Is ZAP70 still a key prognostic factor in early stage chronic lymphocytic leukaemia? Results of the analysis from a prospective multicentre observational study. Br J Haematol 2014 0.76
43 Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options. Hematol Oncol 2011 0.75
44 Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity. Turk J Haematol 2015 0.75
45 Disappearance of acquired hemophilia A after complete remission in a Multiple Myeloma patient. Turk J Haematol 2017 0.75
46 Interleukin 22 is increased and correlated with CD38 expression in patients with B-chronic lymphocytic leukemia. Blood Cells Mol Dis 2012 0.75
47 Exacerbation of chronic idiopathic thrombocytopenic purpura following reactivation of an occult hepatitis B. Med Oncol 2009 0.75
48 Differences in transplant-related complications between hematologic malignancies and solid tumors receiving high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Tumori 2003 0.75
49 Spontaneous Healing of Clodronate-Related Osteonecrosis of the Jaw. J Craniofac Surg 2017 0.75
50 Lymphocytes from patients with early stage of B-cell chronic lymphocytic leukaemia and long survival synthesize decorin. Biochimie 2006 0.75
51 Increase in serum protein carbonyl groups is associated with more advanced stage of disease in multiple myeloma patients. Biomarkers 2011 0.75
52 Long-term complete remission in a multiple myeloma patient after Stevens-Johnson syndrome due to lenalidomide therapy. Acta Oncol 2012 0.75
53 Disappearance of Bone Marrow Fibrosis in a Patient with Chronic Myeloid Leukemia Treated with Dasatinib. Chemotherapy 2017 0.75
54 Low-energy laser irradiation promotes cellular damage in glucocorticoid-resistant multiple myeloma cells. Leuk Lymphoma 2014 0.75
55 Imatinib mesylate treatment in a patient with chemoresistant Ph+ acute myeloid leukemia: possible role of Wilms' tumor gene 1. Tumori 2007 0.75
56 Effect of therapeutic plasma exchange on plasma levels of oxidative biomarkers in a patient with thrombotic thrombocytopenic purpura. Eur J Haematol 2014 0.75
57 Purpuric gloves and socks syndrome caused by parvovirus B19 infection. Pediatr Infect Dis J 2003 0.75
58 Relationship between advanced oxidation protein products, advanced glycation end products, and S-nitrosylated proteins with biological risk and MDR-1 polymorphisms in patients affected by B-chronic lymphocytic leukemia. Cancer Invest 2012 0.75
59 Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant. Chemotherapy 2017 0.75
60 Serum levels of interleukin-16 in a multiple myeloma patient with cutaneous involvement. Int J Dermatol 2010 0.75
61 Increase of IL-17, IL-22 and IL-23 serum levels induced by immunoglobulin infusion for Parvovirus-B associated Pure Red Cell Aplasia in a renal transplant recipient. Acta Oncol 2011 0.75